AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30871639 — intervention group
Group type: EXPERIMENTAL
Intervention: deltamethrin with dog collars (DC)
Number of subjects: 788
Study 30871639 — intervention group
Group type: COMPARATOR
Intervention: no insecticide (C)
Number of subjects: 788
Study 29534330 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid micelles (500 mg vineatrol, 30 mg trans-resveratrol, 75 mg trans-ε-viniferin)
Number of subjects: 12
Study 29534330 — intervention group
Group type: COMPARATOR
Intervention: Native powder (500 mg vineatrol, 30 mg trans-resveratrol, 75 mg trans-ε-viniferin)
Number of subjects: 12
Study 27137199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 international units)
Number of subjects: 0
Study 27137199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23434570 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week plus methotrexate 7.5 mg/week (increased to 20 mg/week within 2 months) and intra-articular triamcinolone
Number of subjects: 180
Study 23434570 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate plus placebo-adalimumab and intra-articular triamcinolone
Number of subjects: 180
Study 22610520 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheters (IPC)
Number of subjects: 106
Study 22610520 — intervention group
Group type: COMPARATOR
Intervention: Chest tube and talc slurry pleurodesis (talc)
Number of subjects: 106
Study 19596331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein components (LC), specifically non-high density cholesterol (nHDL-C)
Number of subjects: 1734
Study 19596331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein components (LC)
Number of subjects: 1734
Study 19596331 — intervention group
Group type: COMPARATOR
Intervention: Traditional risk factors (serum creatinine, diabetes, inflammation measured by C-reactive protein)
Number of subjects: 1734
Study 17703897 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior aware participants
Number of subjects: 0
Study 17703897 — intervention group
Group type: EXPERIMENTAL
Intervention: Serendipitously aware participants
Number of subjects: 0
Study 17703897 — intervention group
Group type: COMPARATOR
Intervention: Unaware participants
Number of subjects: 0
Study 17703897 — intervention group
Group type: EXPERIMENTAL
Intervention: Serendipitously aware group
Number of subjects: 0
Study 17703897 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior aware group
Number of subjects: 0
Study 16470487 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 181
Study 16470487 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 181
Study 11772845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomised studies
Number of subjects: 0
Study 11772845 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-experimental designs
Number of subjects: 0
Study 10365000 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife top-ups (group MW, n = 43)
Number of subjects: 133
Study 10365000 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (group PCEA, n = 44)
Number of subjects: 133
Study 10365000 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (group Cl, n = 46)
Number of subjects: 133
Study 10365000 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (group Cl)
Number of subjects: 133
Study 10365000 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife top-ups (group MW)
Number of subjects: 133
Study 10365000 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (group PCEA)
Number of subjects: 133
Study 10365000 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 133
Study 7554701 — intervention group
Group type: EXPERIMENTAL
Intervention: 2400 mg/day felbamate
Number of subjects: 24
Study 7554701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2201727 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0
Study 2201727 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 7261663 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical thrombin
Number of subjects: 102
Study 7261663 — intervention group
Group type: COMPARATOR
Intervention: Control group (no topical thrombin)
Number of subjects: 102
Study 30629046 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg body mass)
Number of subjects: 27
Study 30629046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 28486692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/S-1 (CS)
Number of subjects: 132
Study 28486692 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin/S-1 (DCS)
Number of subjects: 132
Study 26427562 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextually-tailored intervention delivered by trained health coaches using advanced geographic information system tools, linking families to community resources, with support modalities including text messages and virtual visits over a one-year period.
Number of subjects: 0
Study 26427562 — intervention group
Group type: COMPARATOR
Intervention: Enhanced pediatric care plus non-tailored health coaching (Control group).
Number of subjects: 0
Study 23812464 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneously every 6 months)
Number of subjects: 833
Study 23812464 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate (150 mg orally every month)
Number of subjects: 833
Study 23812464 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 833
Study 23812464 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate
Number of subjects: 833
Study 20884788 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care biomarker panel assessment
Number of subjects: 2243
Study 19111476 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked clavicle reconstruction plate in anterior-inferior position
Number of subjects: 24
Study 19111476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlocked clavicle reconstruction plate in anterior-inferior position
Number of subjects: 24
Study 19111476 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked clavicle reconstruction plate in superior position
Number of subjects: 24
Study 19111476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlocked clavicle reconstruction plate in superior position
Number of subjects: 24
Study 19111476 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior plates (locked and nonlocked)
Number of subjects: 24
Study 19111476 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior-inferior plates
Number of subjects: 24
Study 17725176 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg probenecid 3 times daily for 2 days
Number of subjects: 7
Study 17725176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 14996698 — intervention group
Group type: EXPERIMENTAL
Intervention: Self taught training package
Number of subjects: 3
Study 14996698 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at a training workshop
Number of subjects: 3
Study 14996698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 14996698 — intervention group
Group type: EXPERIMENTAL
Intervention: Self taught training package and Attendance at a training workshop
Number of subjects: 3
Study 11493492 — intervention group
Group type: EXPERIMENTAL
Intervention: Model simulation (MF)
Number of subjects: 54
Study 11493492 — intervention group
Group type: EXPERIMENTAL
Intervention: Model simulation (MF) after calibration
Number of subjects: 54
Study 11493492 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 54
Study 11493492 — intervention group
Group type: EXPERIMENTAL
Intervention: Model simulation (MF) during surgery
Number of subjects: 54
Study 11493492 — intervention group
Group type: EXPERIMENTAL
Intervention: Model simulation (MF) with consecutive measurements
Number of subjects: 54
Study 9764982 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon plus ofloxacin (600 mg daily)
Number of subjects: 55
Study 9764982 — intervention group
Group type: COMPARATOR
Intervention: Alpha-interferon alone
Number of subjects: 55
Study 9764982 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (alpha-interferon plus ofloxacin)
Number of subjects: 55
Study 7844205 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose step-down hormone replacement therapy (HRT)
Number of subjects: 0
Study 3042355 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 412
Study 3042355 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 412
Study 3042355 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (combination therapy)
Number of subjects: 412
Study 3042355 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (combination therapy)
Number of subjects: 412
Study 31691370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 162
Study 31691370 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 162
Study 31691370 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone implant
Number of subjects: 162
Study 31691370 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 162
Study 31691370 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 162
Study 31691370 — intervention group
Group type: EXPERIMENTAL
Intervention: Phakic patients
Number of subjects: 162
Study 29945395 — intervention group
Group type: EXPERIMENTAL
Intervention: Huazhuo Jiedu formula, 1 dose/day for 6 months
Number of subjects: 70
Study 29945395 — intervention group
Group type: COMPARATOR
Intervention: Alatan Wuwei Wan, bid, 1 bag/time for 6 months
Number of subjects: 70
Study 27760697 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Compression Stocking (ECS)
Number of subjects: 400
Study 27760697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ECS)
Number of subjects: 400
Study 24926629 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Wave Vibration (BWV) training
Number of subjects: 31
Study 24926629 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar yoga exercises without rhythmic components)
Number of subjects: 31
Study 22828090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine/HCT 150/5/12.5 mg (week 4)
Number of subjects: 1191
Study 22828090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine/HCT 300/10/25 mg (week 8)
Number of subjects: 1191
Study 22828090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine/HCT 150/5/12.5 mg (week 2)
Number of subjects: 1191
Study 22828090 — intervention group
Group type: COMPARATOR
Intervention: Dual combinations (aliskiren/amlodipine 150/5 mg, aliskiren/HCT 150/12.5 mg, amlodipine/HCT 5/12.5 mg)
Number of subjects: 1191
Study 22828090 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination (aliskiren/amlodipine/HCT)
Number of subjects: 1191
Study 19765266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 252
Study 19765266 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitor (Control)
Number of subjects: 252
Study 18348746 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hFSH (300 IU)
Number of subjects: 97
Study 18348746 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hLH (450 IU)
Number of subjects: 97
Study 18348746 — intervention group
Group type: COMPARATOR
Intervention: r-hLH/r-hFSH (fixed combination)
Number of subjects: 97
Study 15888156 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x weekly treatment
Number of subjects: 14
Study 15888156 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x weekly treatment
Number of subjects: 14
Study 15888156 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x weekly treatment
Number of subjects: 14
Study 12698396 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuit
Number of subjects: 88
Study 12698396 — intervention group
Group type: COMPARATOR
Intervention: Uncoated extracorporeal circuit
Number of subjects: 88
Study 10353862 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg/day for 4 weeks
Number of subjects: 24
Study 10353862 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 24
Study 8943671 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin 120 mg/m2 and etoposide 100 mg/m2 i.v. for 3 days, every fourth week) followed by radiotherapy (56 Gy to the chest)
Number of subjects: 302
Study 8943671 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (56 Gy to the chest)
Number of subjects: 302
Study 1777371 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 20
Study 1777371 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg)
Number of subjects: 20
Study 1777371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7307569 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsified lanolin and mineral oil bath additive
Number of subjects: 0
Study 7307569 — intervention group
Group type: COMPARATOR
Intervention: Usual bath soap
Number of subjects: 0
Study 30665439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1000 mg)
Number of subjects: 19
Study 30665439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29165598 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg)
Number of subjects: 258
Study 29165598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 26475347 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical clowning
Number of subjects: 100
Study 26475347 — intervention group
Group type: COMPARATOR
Intervention: EMLA (local anesthetic cream)
Number of subjects: 100
Study 26475347 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clown, no EMLA)
Number of subjects: 100
Study 24172652 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens (SCL) applied post-surgery
Number of subjects: 63
Study 24172652 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic pomade with bandage (control)
Number of subjects: 63
Study 23109694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (30 mg injection)
Number of subjects: 80
Study 23109694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23109694 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 80
Study 19022433 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood serum of endometriosis patients
Number of subjects: 59
Study 19022433 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative blood serum of endometriosis patients
Number of subjects: 59
Study 19022433 — intervention group
Group type: COMPARATOR
Intervention: CA-125
Number of subjects: 59
Study 17963528 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for mild gestational diabetes mellitus (dietary advice, blood glucose monitoring, insulin therapy as needed)
Number of subjects: 0
Study 17963528 — intervention group
Group type: COMPARATOR
Intervention: Routine pregnancy care
Number of subjects: 0
Study 15678734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.15 microg kg(‐1)
Number of subjects: 63
Study 15678734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.30 microg kg(‐1)
Number of subjects: 63
Study 12093058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose amiodarone (200 mg/day)
Number of subjects: 392
Study 9811284 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel moist wound dressing (Elasto-gel)
Number of subjects: 42
Study 9811284 — intervention group
Group type: COMPARATOR
Intervention: Breast shells and lanolin cream
Number of subjects: 42
Study 7658603 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy oligosaccharide fiber (75 g/L)
Number of subjects: 13
Study 7658603 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy polysaccharide fiber (20 g/L)
Number of subjects: 13
Study 7658603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat fiber (15 g/L)
Number of subjects: 13
Study 7658603 — intervention group
Group type: COMPARATOR
Intervention: Fiber-free diet
Number of subjects: 13
Study 7658603 — intervention group
Group type: COMPARATOR
Intervention: Self-selected diet
Number of subjects: 13
Study 2704504 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (Premarin) + 5 mg medroxyprogesterone acetate (Provera)
Number of subjects: 95
Study 2704504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogen (Premarin) + 5 mg medroxyprogesterone acetate (Provera)
Number of subjects: 95
Study 2704504 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (Premarin) + placebo
Number of subjects: 95
Study 2704504 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogen (Premarin) + placebo
Number of subjects: 95
Study 407817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cromolyn therapy
Number of subjects: 16
Study 407817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31928314 — intervention group
Group type: EXPERIMENTAL
Intervention: WAIS-R Block Design subtest
Number of subjects: 183
Study 31928314 — intervention group
Group type: EXPERIMENTAL
Intervention: WAIS-R Arithmetic subtest
Number of subjects: 183
Study 31928314 — intervention group
Group type: COMPARATOR
Intervention: Existing norms for English-speakers
Number of subjects: 183
Study 31321541 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP-targeted treatments
Number of subjects: 0
Study 27761732 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg vaginal progesterone suppository twice daily
Number of subjects: 400
Study 27761732 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral dydrogesterone twice daily
Number of subjects: 400
Study 27761732 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral dydrogesterone twice daily combined with 0.1 mg GnRH‐α
Number of subjects: 400
Study 27761732 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral dydrogesterone twice daily combined with 1500 IU hCG
Number of subjects: 400
Study 27761732 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 400
Study 25345840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bevacizumab with antiretroviral therapy
Number of subjects: 14
Study 25345840 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy alone (Control)
Number of subjects: 14
Study 23539110 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) dosing strategy
Number of subjects: 38
Study 21594828 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin administration (Hep [+])
Number of subjects: 480
Study 21594828 — intervention group
Group type: COMPARATOR
Intervention: No heparin administration (Hep [‐])
Number of subjects: 480
Study 19155456 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 to 20 mg/d for 12 weeks)
Number of subjects: 177
Study 19155456 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 177
Study 19155456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 16487841 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 32
Study 16487841 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Inspiratory Muscle Training (P-IMT)
Number of subjects: 32
Study 15250844 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐D PSMA (life size picture of tennis and golf balls)
Number of subjects: 113
Study 15250844 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐D PSMAs (tennis and golf balls)
Number of subjects: 113
Study 15250844 — intervention group
Group type: COMPARATOR
Intervention: None (Control for Food Set 1 and Food Set 3)
Number of subjects: 113
Study 11277342 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor therapy (enalapril maleate, imidapril hydrochloride, trandolapril)
Number of subjects: 75
Study 9309743 — intervention group
Group type: COMPARATOR
Intervention: SVC position (n = 10, group A)
Number of subjects: 17
Study 9309743 — intervention group
Group type: EXPERIMENTAL
Intervention: Left subclavian vein position (n = 7, group B)
Number of subjects: 17
Study 7901049 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 7901049 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 0
Study 7901049 — intervention group
Group type: COMPARATOR
Intervention: Tulobuterol
Number of subjects: 0
Study 3518855 — intervention group
Group type: EXPERIMENTAL
Intervention: EEA stapling gun
Number of subjects: 100
Study 3518855 — intervention group
Group type: COMPARATOR
Intervention: Hand suture using a single layer of interrupted sutures
Number of subjects: 100
Study 31164313 — intervention group
Group type: EXPERIMENTAL
Intervention: A + FMS intervention
Number of subjects: 282
Study 31164313 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 282
Study 27743129 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-h Oral Fat Tolerance Test (OFTT) without prior exercise
Number of subjects: 21
Study 27743129 — intervention group
Group type: COMPARATOR
Intervention: 4-h Oral Fat Tolerance Test (OFTT) with 1-h prior aerobic exercise
Number of subjects: 21
Study 27093772 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B 3D White Radiant
Number of subjects: 0
Study 27093772 — intervention group
Group type: COMPARATOR
Intervention: Positive Control (PC) manual brush
Number of subjects: 0
Study 25300874 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent online sleep intervention (sleep information, sleep hygiene education, cognitive behavioral therapy)
Number of subjects: 134
Study 25300874 — intervention group
Group type: COMPARATOR
Intervention: Standardized cardiovascular risk factor and lifestyle-education session (usual care)
Number of subjects: 134
Study 22042636 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma total omega-3
Number of subjects: 109
Study 22042636 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (0.1 unit)
Number of subjects: 109
Study 20603300 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music
Number of subjects: 47